Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors

1. A method of treating a disease or condition in which c-kit receptor activity contributes to the pathology or symptomology of the disease or condition, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the structure of Formula (1) or Formula (46), or a pharmaceutically acceptable salt thereof,

wherein the disease or condition is selected from asthma, allergic sinusitis, allergic rhinitis, atopic dermatitis, allergic contact dermatitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, psoriasis, pulmonary fibrosis, liver fibrosis, scleroderma, irritable bowel syndrome, idiopathic pulmonary arterial hypertension and primary pulmonary hypertension, and

wherein:

Ar is selected from an optionally substituted five-membered aromatic heterocycle, an optionally substituted five-membered aromatic carbocycle, an optionally substituted six-membered aromatic heterocycle, and a substituted, optionally further substituted phenyl;

Q is selected from the group consisting of

or

Q is selected from the group consisting of

wherein:

R A is selected from —NH 2 , —NEt 2 , and —NH(CH 2 ) n OH, and n is 1 to;

R B is selected from the group consisting of

—CH 2 OH, —CH 2 CH 2 OH, and —CH 2 CH 2 CH 2 OH;

R C is at 2, 3, or 4 position of the piperidine ring; and R C is selected from the group consisting of —C(O)NHEt, —C(O)NEt 2 , c-butyl, c-pentyl, —C(O)NH— thiazole, oxazole, thiazole, —S(O) 2 NH 2 , —S(O) 2 NHEt, and —S(O) 2 NEt 2 ;

each R D is independently selected from —(CH 2 ) k OH or —(CH 2 ) k CO 2 H, and k is 1 to 6;

R E is at 2, 3, or 4 position of the piperidine ring; and R E is selected from the group consisting of —C(O)NH 2 , —C(O)NHEt, and —C(O)NEt 2 , and

R F is thiazole, pyrazole, or isoxazole;

each R 1 is independently selected from the group consisting of H, halogen, and an optionally substituted moiety selected from —L 1 -alkyl, —L 1 -cycloalkyl, —L 1 -heteroalkyl, —L 1 -haloalkyl, —L 1 -aryl, —L 1 -heterocycloalkyl, and —L 1 -heteroaryl; wherein L 1 is selected from a bond, —O—, —NH—, —S—, —C(O)—, —C(S)—, —C(O)O—, —C(O)NH—, —S(O)—, —S(O) 2 —, —C(O)NH(CR″ 2 ) 1-6 C(O)O—, —C(O)NR″NR″C(O)O—, and —S(O)NH—;

each R″ is independently H, OH, halogen, C 1-6 alkyl, substituted C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkyl, halo-C 1-6 alkoxy, aryl, haloaryl, or heteroaryl;

or any two adjacent R 1 groups together may form an optionally substituted 5 to 8-membered heterocyclic, cycloalkyl, or aryl ring; and

R 5 is selected from the group consisting of hydrogen and C 1-6 alkyl

and wherein,

the compound is an inhibitor of c-kit receptor activity.

2. The method of claim 1 , wherein the Ar is a substituted, optionally further substituted six-membered aromatic heterocycle.

3. The method of claim 1 , wherein said optional substituents are selected from OH, halogen, C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkyl, halo-C 1-6 alkoxy, aryl, haloaryl, or heteroaryl.

4. The method of claim 1 , wherein Ar is selected from the group consisting of

5. The method of claim 1 , wherein Q is selected from the group consisting of

6. The method of claim 4 , wherein Ar is selected from the group consisting of

7. The method of claim 1 , wherein the compound having the structure of Formula (1) is selected from a compound having a structure according to Formula (2), Formula (3), or Formula (44):

wherein:

M is selected from the group consisting of H, OH, SH, NO 2 , CN, NR″ 2 , and an optionally substituted moiety selected from —L 7 -alkyl, —L 7 -cycloalkyl, —L 7 -heteroalkyl, —L 7 -haloalkyl, —L 7 -aryl, —L 7 -heterocycloalkyl, and —L 7 -heteroaryl; wherein L 7 is selected from a bond, —O—, —NH—, —S—, —C(O)—, —C(S)—, —C(O)O—, —C(O)NH—, —S(O)—, —S(O) 2 —, —OC(O)—, —C(O)NR″ (CR″ 2 ) 1-6 C(O)O—, —CR″ 2 NR″CR″ 2 C(O)O—, —C(O)NR″Y 1 C(O)O—, —C(O)NR″NR″C(O)O—, —S(O)NH—, —C(O)NR″CR″ 2 C(O)W—, —CR″NR″WO—, —CR″NR″Y 1 C(O)O—, and —C(O)NR″O—; W is C 1-6 alkylene; Y 1 is optionally substituted arylene or optionally substituted heteroarylene; wherein said optional substituents are selected from halogen, OH, C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkyl and halo-C 1-6 alkoxy; provided that M is not H in Formula (2);

each R″ is independently H, OH, halogen, C 1-6 alkyl, substituted C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkyl, halo-C 1-6 alkoxy, aryl, haloaryl, or heteroaryl;

each X is independently selected from N or CR 2 , provided that at least one but no more than 2 X groups are N;

each R 2 is independently selected from the group consisting of H, OH, halogen, and an optionally substituted moiety selected from —L 2 -alkyl, —L 2 -cycloalkyl, —L 2 -heteroalkyl, —L 2 -haloalkyl, —L 2 -aryl, —L 2 -heterocycloalkyl, and —L 2 -heteroaryl; wherein L 2 is selected from a bond, —O—, —NH—, —S—, —C(O)—, —C(S)—, —C(O)O—, —C(O)NH—, —S(O)—,

—S(O) 2 —, —C(O)NR″ (CR″ 2 ) 1-6 C(O)O—, —OC(O)—, —CR″NR″CR″C(O)O—, —C(O)NR″NR″C(O)O—, and —S(O)NH—; wherein said optional substituents are selected from halogen, OH, C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkyl and halo-C 1-6 alkoxy;

or any two adjacent R 2 groups together may form an optionally substituted 5 to 8-membered heterocyclic, cycloalkyl, or aryl ring;

or a pharmaceutically acceptable salt or pharmaceutically acceptable N-oxide thereof.

8. The method of claim 1 , wherein the compound having the structure of Formula (46) is selected from a compound having a structure according to Formula (47), Formula (48), or Formula (49):

wherein:

M is selected from the group consisting of H, OH, SH, NO 2 , CN, NR″ 2 , and an optionally substituted moiety selected from —L 7 -alkyl, —L 7 -cycloalkyl, —L 7 -heteroalkyl, —L 7 -haloalkyl, —L 7 -aryl, —L 7 -heterocycloalkyl, and —L 7 -heteroaryl; wherein L 7 is selected from a bond, —O—, —NH—, —S—, —C(O)—, —C(S)—, —C(O)O—, —C(O)NH—, —S(O)—, —S(O) 2 —, —OC(O)—, —C(O)NR″ (CR″) 1-6 C(O)O—, —CR″ 2 NR″CR″C(O)O—, —C(O)NR″Y 1 C(O)O—, —C(O)NR″NR″C(O)O—, —S(O)NH—, —C(O)NR″CR″ 2 C(O)W—, —CR″ 2 NR″WO—, —CR″ 2 NR″Y 1 C(O)O—, and —C(O)NR″O—;

W is C 1-6 alkylene;

Y 1 is optionally substituted arylene or optionally substituted heteroarylene; wherein said optional substituents are selected from halogen, OH, C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkyl and halo-C 1-6 alkoxy;

provided that M is not H in Formula (47);

each R″ is independently H, OH, halogen, C 1-6 alkyl, substituted C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkyl, halo-C 1-6 alkoxy, aryl, haloaryl, or heteroaryl;

each X is independently selected from N or CR 2 , provided that at least one but no more than 2 X groups are N;

each R 2 is independently selected from the group consisting of H, OH, halogen, and an optionally substituted moiety selected from —L 2 -alkyl, —L 2 -cycloalkyl, —L 2 -heteroalkyl, —L 2 -haloalkyl, —L 2 -aryl, —L 2 -heterocycloalkyl, and —L 2 -heteroaryl; wherein L 2 is selected from a bond, —O—, —NH—, —S—, —C(O)—, —C(S)—, —C(O)O—, —C(O)NH—, —S(O)—, —S(O) 2 —, —C(O)NR″(CR″ 2 ) 1-6 C(O)O—, —OC(O)—, —CR″ 2 NR″CR″ 2 C(O)O—, —C(O)NR″NR″C(O)O—, and —S(O)NH—; wherein said optional substituents are selected from halogen, OH, C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkyl and halo-C 1-6 alkoxy;

or any two adjacent R 2 groups together may form an optionally substituted 5 to 8-membered heterocyclic, cycloalkyl, or aryl ring;

or a pharmaceutically acceptable salt or pharmaceutically acceptable N-oxide thereof.

9. The method of claim 1 , wherein the compound having the structure of Formula (1) is selected from a compound having a structure according to Formula (23), Formula (24) or Formula (45):

wherein:

M is selected from the group consisting of H, OH, SH, NO 2 , CN, NR″ 2 , and an optionally substituted moiety selected from —L 7 -alkyl, —L 7 -cycloalkyl, —L 7 -heteroalkyl, —L 7 -haloalkyl, —L 7 -aryl, —L 7 -heterocycloalkyl, and —L 7 -heteroaryl; wherein L 7 is selected from a bond, —O—, —NH—, —S—, —C(O)—, —C(S)—, —C(O)O—, —C(O)NH—, —S(O)—, —S(O) 2 —, —OC(O)—, —S(O)NH—, —CR″ 2 NR″CR″ 2 C(O)O—, —C(O)NR″(CR″ 2 ) 1-6 C(O)O—, —C(O)NR″Y 1 C(O)O—, —CR″ 2 NR″WO—, —C(O)NR″NR″C(O)O—, —C(O)NR″CR″ 2 C(O)W—, —CR″ 2 NR″Y 1 C(O)O—, and —C(O)NR″O—;

W is C 1-6 alkylene;

Y 1 is optionally substituted arylene or optionally substituted heteroarylene; wherein said optional substituents are selected from halogen, OH, C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkyl and halo-C 1-6 alkoxy;

each R″ is independently H, OH, halogen, C 1-6 alkyl, substituted C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkyl, halo-C 1-6 alkoxy, aryl, haloaryl, or heteroaryl;

provided that M is not H in Formula (23) and Formula (50);

each X is independently selected from N or CR 2 , provided that at least one but no more than 2 X groups are N;

each R 1 is independently an optionally substituted moiety selected from —L 1 -H or —L 1 -alkyl; wherein L 1 is selected from a bond, —O—, —NH—, —S—, —C(O)—, —C(S)—, —C(O)O—, —C(O)NH—, —S(O)—, —S(O) 2 —, —C(O)NH(CR″ 2 ) 1-6 C(O)O—, —C(O)NR″NR″C(O)O— and —S(O)NH—;

R 5 is selected from the group consisting of hydrogen and C 1-6 alkyl;

each R 2 is independently selected from the group consisting of H, OH, halogen, and an optionally substituted moiety selected from —L 2 -alkyl, —L 2 -cycloalkyl, —L 2 -heteroalkyl, —L 2 -haloalkyl, —L 2 -aryl, —L 2 -heterocycloalkyl, and —L 2 -heteroaryl; wherein L 2 is selected from a bond, —O—, —NH—, —S—, —C(O)—, —C(S)—, —C(O)O—, —C(O)NH—, —S(O)—, —S(O) 2 —, —C(O)NR″ (CR″ 2 ) 1-6 C(O)O—, —OC(O)—, —CR″ 2 NR″CR″ 2 C(O)O—, —C(O)NR″NR″C(O)O—, and —S(O)NH—; wherein said optional substituents are selected from halogen, OH, C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkyl, and halo-C 1-6 alkoxy; or any two adjacent R 2 groups together may form an optionally substituted 5 to 8-membered heterocyclic, cycloalkyl, or aryl ring;

each of R 3 and R 4 is independently an optionally substituted moiety selected from —Z, —L 3 —Z, —L 3 -H, —L 3 -alkyl, —L 3 -cycloalkyl, —L 3 -heteroalkyl, —L 3 -haloalkyl, —L 3 -aryl, —L 3 -heterocycloalkyl, and —L 3 -heteroaryl; wherein L 3 is selected from a bond, —C(S)—, —C(O)O—, —C(O)NR′″—, —(CR″) 1-6 —, —CR′″ 2 S(O)—, —CR′″ 2 S(O) 2 —, —CR′″ 2 S(O)NR′″—, —CR′″ 2 C(O)NR′″—, —(CR′″ 2 ) 1-6 NR′″—, —(CR′″ 2 ) 1-6 O—, —(CR′″ 2 ) 1-6 C(O)O—, —Y 2 C(O)O—, and an optionally substituted C 1-6 alkylene; wherein said optional substituents are selected from halogen, —OH, ═O, —Y 3 , C 1-6 alkyl, C 1-6 alkoxy, halogen or OH substituted C 1-6 alkyl, halogen or OH substituted C 1-6 alkoxy, —(CR′″ 2 ) 1-6 C(O)OR 6 , —C(O)NR′″ 2 , —C(O)R 6 , or —C(O)OR 6 ;

Y 2 is an optionally substituted cycloalkyl ring or optionally substituted non-aromatic heterocyclic ring; wherein said optional substituents are selected from C 1-6 alkyl, halogen, —OH, ═O, and —CN;

Y 3 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted non-aromatic heterocycle; wherein said optional substituents are selected from C 1-6 alkyl, halogen, —OH, ═O, and —CN;

Z is —H, —OH, —CN, —COOR′″, —NR′″ 2 , or —C≡CR′″;

each R′″ is independently H, alkyl, or substituted alkyl; or two R′″ together may form a 3-6 membered cycloalkyl or heterocyclic ring;

or R 3 and R 4 taken together with the N atom to which they are attached may form an optionally substituted 3 to 8-membered heterocyclic ring; wherein said optional substituents are selected from halogen, —OH, ═O, —Y 3 , C 1-6 alkyl, C 1-6 alkoxy, halogen or OH substituted C 1-6 alkyl, halogen or OH substituted C 1-6 alkoxy, —(CR′″ 2 ) 1-6 Y 4 , —(CR′″ 2 ) 1-6 OR 6 , —C(O)NR′″R 6 , —C(O)OR 6 , —OR 6 , —NR′″C(O)OR 6 , —NR′″C(O)R 6 , —(CR′″ 2 ) 1-6 C(O)OR 6 , —(CR′″ 2 ) 1-6 NR′″C(O)OR 6 , —(CR′″ 2 ) 1-6 NR 7 R 8 , —S(O) 2 NR′″ 2 , —C(O)R 6 , —OC(O)R 6 , —NR 7 R 8 , —(CR′″ 2 ) 1-6 C(O)NR 7 R 8 , —S(O) 2 R A , or —C(O)R A ;

Y 4 is aryl, heteroaryl, cycloalkyl, or non-aromatic heterocycle;

R A is selected from —NH 2 , —NEt 2 , and —NH(CH 2 ) 1-6 OH;

R 6 is H, alkyl, substituted alkyl, cycloalkyl, non-aromatic heterocycle, aryl, or heteroaryl;

each of R 7 and R 8 is independently H, OH, halogen, C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkyl, or halo-C 1-6 alkoxy; or R 7 and R 8 taken together with the N atom to which they are attached may form a 3 to 6-membered heterocyclic ring,

and

T 1 is an optionally substituted moiety selected from —L 4 -, -alkylene—L 4 -, —L 4 -alkylene-, —L 4 -cycloalkylene-, —L 4 -heteroalkylene-, —L 4 -haloalkylene-, —L 4 -arylene-, —L 4 -heteroarylene-, and —L 4 -heterocycloalkylene-; wherein L 4 is selected from a bond, —O—, —NH—, —S—, —CR″—, —NR′″C(O)—, —C(O)—, —C(S)—, —C(O)O—, —C(O)NR′″—, —S(O)—, —S(O) 2 —, —OC(O)—, —C(O)NR′″(CR″ 2 ) 1-6 C(O)O—, —C(O)NR′″(CR″) 1-6 C(O)—, —CR″NR′″CR″C(O)O—, —C(O)NR′″NR′″C(O)O—, —C(O)NR′″(CR″ 2 ) 1-6 —, —CR″ 2 C(O)—, and —S(O)NH—; wherein said optional substituents are selected from halogen, OH, C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkyl, halo-C 1-6 alkoxy, aryl, haloaryl, and heteroaryl.

10. The method of claim 9 , wherein each R 2 is H.

11. The method of claim 1 , wherein the compound having the structure of Formula (46) is selected from a compound having a structure according to Formula (50), Formula (51), or Formula (52):

wherein:

M is selected from the group consisting of H, OH, SH, NO 2 , CN, NR″ 2 , and an optionally substituted moiety selected from —L 7 -alkyl, —L 7 -cycloalkyl, —L 7 -heteroalkyl, —L 7 -haloalkyl, —L 7 -aryl, —L 7 -heterocycloalkyl, and —L 7 -heteroaryl; wherein L 7 is selected from a bond, —O—, —NH—, —S—, —C(O)—, —C(S)—, —C(O)O—, —C(O)NH—, —S(O)—, —S(O) 2 —, —OC(O)—, —S(O)NH—, —CR″ 2 NR″CR″ 2 C(O)O—, —C(O)NR″(CR″ 2 ) 1-6 C(O)O—, —C(O)NR″Y 1 C(O)O—, —CR″ 2 NR″WO—, —C(O)NR″NR″C(O)O—, —C(O)NR″CR″C(O)W—, —CR″NR″Y 1 C(O)O—, and —C(O)NR″O—;

W is C 1-6 alkylene;

Y 1 is optionally substituted arylene or optionally substituted heteroarylene; wherein said optional substituents are selected from halogen, OH, C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkyl and halo-C 1-6 alkoxy;

each R″ is independently H, OH, halogen, C 1-6 alkyl, substituted C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkyl, halo-C 1-6 alkoxy, aryl, haloaryl, or heteroaryl;

provided that M is not H in Formula (23) and Formula (50);

each X is independently selected from N or CR 2 , provided that at least one but no more than 2 X groups are N;

each R 1 is independently an optionally substituted moiety selected from —L 1 —H or —L 1 -alkyl; wherein L 1 is selected from a bond, —O—, —NH—, —S—, —C(O)—, —C(S)—, —C(O)O—, —C(O)NH—, —S(O)—, —S(O) 2 —, —C(O)NH(CR″ 2 ) 1-6 C(O)O—, —C(O)NR″NR″C(O)O— and —S(O)NH—;

R 5 is selected from the group consisting of hydrogen and C 1-6 alkyl;

each R 2 is independently selected from the group consisting of H, OH, halogen, and an optionally substituted moiety selected from —L 2 -alkyl, —L 2 -cycloalkyl, —L 2 -heteroalkyl, —L 2 -haloalkyl, —L 2 -aryl, —L 2 -heterocycloalkyl, and —L 2 -heteroaryl; wherein L 2 is selected from a bond, —O—, —NH—, —S—, —C(O)—, —C(S)—, —C(O)O—, —C(O)NH—, —S(O)—, —S(O) 2 —, —C(O)NR″(CR″ 2 ) 1-6 C(O)O—, —OC(O)—, —CR″ 2 NR″CR″ 2 C(O)O—, —C(O)NR″NR″C(O)O—, and —S(O)NH—; wherein said optional substituents are selected from halogen, OH, C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkyl, and halo-C 1-6 alkoxy; or any two adjacent R 2 groups together may form an optionally substituted 5 to 8-membered heterocyclic, cycloalkyl, or aryl ring;

each of R 3 and R 4 is independently an optionally substituted moiety selected from —Z, —L 3 —Z, —L 3 -H, —L 3 -alkyl, —L 3 -cycloalkyl, —L 3 -heteroalkyl, —L 3 -haloalkyl, —L 3 -aryl, —L 3 -heterocycloalkyl, and —L 3 -heteroaryl; wherein L 3 is selected from a bond, —C(S)—, —C(O)O—, —C(O)NR′″—, —(CR″ 2 ) 1-6 —, —CR′″ 2 S(O)—, —CR′″ 2 S(O) 2 —, —CR′″ 2 S(O)NR′″—, —CR′″ 2 C(O)NR′″—, —(CR′″ 2 ) 1-6 NR′″—, —(CR′″ 2 ) 1-6 O—, —(CR′″ 2 ) 1-6 C(O)O—, —Y C(O)O—, and an optionally substituted C 1-6 alkylene; wherein said optional substituents are selected from halogen, —OH, ═O, —Y 3 , C 1-6 alkyl, C 1-6 alkoxy, halogen or OH substituted C 1-6 alkyl, halogen or OH substituted C 1-6 alkoxy, —(CR′″ 2 ) 1-6 C(O)OR 6 , —C(O)NR′″ 2 , —C(O)R 6 , or —C(O)OR 6 ;

Y 2 is an optionally substituted cycloalkyl ring or optionally substituted non-aromatic heterocyclic ring; wherein said optional substituents are selected from C 1-6 alkyl, halogen, —OH, ═O, and —CN;

Y 3 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted non-aromatic heterocycle; wherein said optional substituents are selected from C 1-6 alkyl, halogen, —OH, ═O, and —CN;

Z is —H, —OH, —CN, —COOR′″, —NR′″ 2 , or —C≡CR′″;

each R′″ is independently H, alkyl, or substituted alkyl; or two R′″ together may form a 3-6 membered cycloalkyl or heterocyclic ring;

or R 3 and R 4 taken together with the N atom to which they are attached may form an optionally substituted 3 to 8-membered heterocyclic ring; wherein said optional substituents are selected from halogen, —OH, ═O, —Y 3 , C 1-6 alkyl, C 1-6 alkoxy, halogen or OH substituted C 1-6 alkyl, halogen or OH substituted C 1-6 alkoxy, —(CR′″ 2 ) 1-6 Y 4 , —(CR′″ 2 ) 1-6 OR 6 , —C(O)NR′″R 6 , —C(O)OR 6 , —OR 6 , —NR′″C(O)OR 6 , —NR′″C(O)R 6 , —(CR′″ 2 ) 1-6 C(O)OR 6 , —(CR′″ 2 ) 1-6 NR′″C(O)OR 6 , —(CR′″ 2 ) 1-6 NR 7 R 8 , —S(O) 2 NR′″ 2 , —C(O)R 6 , —OC(O)R 6 , —NR 7 R 8 , —(CR′″ 2 ) 1-6 C(O)NR 7 R 8 , —S(O) 2 R A , or —C(O)R A ;

Y 4 is aryl, heteroaryl, cycloalkyl, or non-aromatic heterocycle;

R A is selected from —NH 2 , —NEt 2 , and —NH(CH 2 ) 1-6 OH;

R 6 is H, alkyl, substituted alkyl, cycloalkyl, non-aromatic heterocycle, aryl, or heteroaryl;

each of R 7 and R 8 is independently H, OH, halogen, C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkyl, or halo-C 1-6 alkoxy; or R 7 and R 8 taken together with the N atom to which they are attached may form a 3 to 6-membered heterocyclic ring,

and

T 1 is an optionally substituted moiety selected from —L 4 —, -alkylene—L 4 —, —L 4 -alkylene-, —L 4 -cycloalkylene-, —L 4 -heteroalkylene-, —L 4 -haloalkylene-, —L 4 -arylene-, —L 4 -heteroarylene-, and —L 4 -heterocycloalkylene-; wherein L 4 is selected from a bond, —O—, —NH—, —S—, —CR″—, —NR′″C(O)—, —C(O)—, —C(S)—, —C(O)O—, —C(O)NR′″—, —S(O)—, —S(O) 2 —, —OC(O)—, —C(O)NR′″(CR″) 1-6 C(O)O—, —C(O)NR′″(CR″) 1-6 C(O)—, —CR″NR′″CR″C(O)O—, —C(O)NR′″NR′″C(O)O—, —C(O)NR′″(CR″) 1-6 —, —CR″ 2 C(O)—, and —S(O)NH—; wherein said optional substituents are selected from halogen, OH, C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkyl, halo-C 1-6 alkoxy, aryl, haloaryl, and heteroaryl.

12. The method of claim 11 , wherein each R 2 is H.

13. The method of claim 1 , wherein the compound having the structure of Formula (1) has a structure according to the structure:

14. The method of claim 1 , wherein the compound is selected from the group consisting of:

tert-butyl 2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)-2-fluorobenzamido)acetate,

tert-butyl 2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)-2-fluorobenzylamino)acetate,

tert-butyl 2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzylamino)acetate,

2,2′-(2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenoxy)ethylazanediyl)diethanol,

1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carboxylic acid,

tert-butyl 2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzamido)acetate,

methyl 1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carboxylate,

N-(4-(2-(diethylamino)ethyl)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-amine,

1-(2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenoxy)ethyl)piperidine-4-carboxylic acid,

N-(4-(2-(diethylamino)ethoxy)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-amine,

tert-butyl 2-(4-(2-(4-(2-morpholinoethoxy)phenylamino)pyrimidin-5-yl)benzamido)acetate,

tert-butyl 2-(4-(2-(4-(2-(4-carbamoylpiperidin-1-yl)ethoxy)phenylamino)pyrimidin-5-yl)benzamido)acetate,

4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)phenyl acetate,

ethyl 2-(2-(diethylamino)ethoxy)-5-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoate,

4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl 4-methylpiperazine-1-carboxylate,

5-(4-methoxyphenyl)-N-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)phenyl)pyrimidin-2-amine,

methyl 4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)benzoate,

N-(4-(2-(diethylamino)ethoxy)phenyl)-5-(3-fluoro-4-methoxyphenyl)pyrimidin-2-amine,

2-(2-(diethylamino)ethoxy)-4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoic acid,

methyl 2-(2-(diethylamino)ethoxy)-4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoate,

N-(3-(2-(diethylamino)ethoxy)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-amine,

N-(3-(2-(diethylamino)ethyl)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-amine,

1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine-4-carboxamide,

1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine-3-carboxamide,

tert-butyl 3-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)propanoate,

5-(4-methoxyphenyl)-N-(4-(piperazin-1-ylmethyl)phenyl)pyrimidin-2-amine,

1-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl)ethanone,

(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl)(tetrahydrofuran-2-yl)methanone,

1-(3-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)propyl)pyrrolidin-2-one,

(S)-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidin-2-yl)methanol,

(R)—N-(4-((2-(methoxymethyl)pyrrolidin-1-yl)methyl)phenyl)-5-(4-methoxyphenyl)pyrimidin-2-amine,

1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidin-3-ol,

methyl 1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzylamino)cyclopentanecarboxylate,

4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)-2-methylpiperazine-1-carboxylic acid,

3-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazin-1-yl)propanoic acid,

1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidine-3-carboxylic acid,

ethyl 2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidin-4-yl)acetate,

2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperidin-4-yl)acetic acid,

1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)pyrrolidine-3-carboxylic acid,

3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl morpholine-4-carboxylate,

3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl 4-methylpiperazine-1-carboxylate, 3-(5-(4-((2-tert-butoxy-2-oxoethylamino)methyl)phenyl)pyrimidin-2-ylamino)phenyl 4-methylpiperazine-1-carboxylate,

methyl 4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl)piperazine-1-carboxylate,

4-(5-(4-((2-tert-butoxy-2-oxoethylamino)methyl)phenyl)pyrimidin-2-ylamino)phenyl 4-methylpiperazine-1-carboxylate,

N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-methylpiperazine-1-carboxamide,

2-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-1-(4-methylpiperazin-1-yl)ethanone,

N1-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperidine-1,4-dicarboxamide,

3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzyl 4-methylpiperazine-1-carboxylate,

4-hydroxy-N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperidine-1-carboxamide,

N-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-methylpiperazine-1-carboxamide,

1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-4-carboxamide,

furan-2-yl(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperazin-1-yl)methanone,

5-(4-methoxyphenyl)-N-(4-(2-(piperazin-1-yl)ethyl)phenyl)pyrimidin-2-amine,

N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-N,4-dimethylpiperazine-1-carboxamide,

1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-3-carboxamide,

1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-3-carboxylic acid,

methyl 4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperazine-1-carboxylate,

1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-3-carboxylic acid,

2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidin-4-yl)acetic acid, methyl 2-(1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidin-4-yl)acetate,

(3-(hydroxymethyl)piperidin-1-yl)(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)methanone,

(3-hydroxypyrrolidin-1-yl)(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)methanone,

1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine-4-carboxamide,

3-(4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperazin-1-yl)propanoic acid,

(S)-1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)pyrrolidine-2-carboxylic acid,

4-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethylamino)cyclohexanecarboxylic acid,

4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(3-(2-oxopyrrolidin-1-yl)propyl)benzamide,

1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine-3-carboxamide,

N-(3-carbamoylphenyl)-4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzamide,

1,4′-bipiperidin-1′-yl(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)methanone,

(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(pyrrolidin-1-yl)piperidin-1-yl)methanone,

4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(2-(pyridin-2-yl)ethyl)benzamide,

4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzamide,

(4-(furan-2-carbonyl)piperazin-1-yl)(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)methanone,

3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzamide,

(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(1-methylpiperidin-4-yl)piperazin-1-yl)methanone,

1-(4-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperazin-1-yl)ethanone,

(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(4-(pyrrolidin-1-yl)piperidin-1-yl)methanone,

1,4′-bipiperidin-1′-yl(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)methanone,

1-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)benzoyl)piperidine-3-carboxamide,

N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)-4-(1-methylpiperidin-4-yl)piperazine-1-carboxamide,

methyl 4-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenylcarbamoyl)piperazine-1-carboxylate,

(R)-1-(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenethyl)piperidine-3-carboxylic acid,

(4-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(piperazin-1-yl)methanone,

4-acetyl-N-(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)piperazine-1-carboxamide, and

(3-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)phenyl)(piperazin-1-yl)methanone.